Business

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a

articleCollegium Pharmaceutical, Inc.April 1, 20253/company/collegium-pharmaceutical-inc/news/collegium-participate-24th-annual-needham-virtual-healthcare-conference-2025-04-01
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

About this update from Collegium Pharmaceutical, Inc.

[{"type":"text","content":"STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com. Investor Contacts:Ian KarpHead of Investor [email protected] Danielle JesseDirector, Investor [email protected] Media Contact:Cheryl WheelerHead of Corporate [email protected] \nSource: Collegium Pharmaceutical, Inc.","length":5939,"tagName":"div"}]

More updates from Collegium Pharmaceutical, Inc.